HAYWARD, Calif., Nov. 14, 2011 /PRNewswire/ -- GenturaDx today announced that it will present data from alpha studies performed in Q2 2011 at the Association for Molecular Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 p.m. to 3:30 p.m. Poster number ID 23 titled "Comparison Of Assay Performance Between Cell Culture And A Rapid Automated Molecular Test For HSV Typing Of Clinical Samples" will address the capability of the GenturaDx IDbox™ System to detect HSV 1/2 as compared with non-molecular methods. Lead author Nathalie Visomblin, Chief Scientific Officer/Co-Founder Dr. Jesus Ching, and Senior Vice President of Research and Development Dr. Geoff McKinley will be on hand to answer questions.
The GenturaDx IDbox™ System will be on display at booth 721. GenturaDx's fully automated molecular diagnostics platform, the IDbox™ System and its initial HSV 1/2 assay, are currently in beta testing with clinical trials beginning in 2012. The IDbox™ System is a compact, fully integrated system that can handle multiple sample types and assay chemistry options. With a broad menu of infectious disease tests and a true press play and walk away technology, the IDbox™ System will be the first to enable labs to meet both increasing clinical demand for molecular testing while maximizing laboratory efficiency.
GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection, reducing the risk of contamination and saving time. The platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to www.GenturaDx.com.
Copyright©2010 PR Newswire.
All rights reserved